Skip to Main Content

Amgen and the biotech startup Arrakis Therapeutics announced a research collaboration Tuesday to discover and develop a new class of oral drugs that selectively destroy RNA molecules that turn genetic instructions into disease-causing proteins.

Called “targeted RNA degraders,” this emerging technology will go after targets that traditional drug-development methods can’t reach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment